CULLINAN THERAPEUTICS INC (CGEM) — insider trading
Health Care · NASDAQ
CULLINAN THERAPEUTICS INC (CGEM) has 19 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 19 (latest 2026-07-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-06 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 4,000 | $0.00 | $0 | Form 4 |
| 2026-07-06 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Open-market sale | 8,000 | $17.82 | $142.6K | Form 4 |
| 2026-07-06 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Option exercise / conversion | 4,000 | $4.30 | $17.2K | Form 4 |
| 2026-06-30 | Fenton Mary Kay | Officer (Chief Financial Officer) | Grant / award / vesting | 1,541 | $8.60 | $13.3K | Form 4 |
| 2026-06-30 | SUMER JACQUELYN L | Officer (Chief Legal Officer) | Grant / award / vesting | 2,470 | $8.60 | $21.2K | Form 4 |
| 2026-06-16 | Doyle Mittie | Director | Grant / award / vesting (derivative) | 21,781 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Thistle Mary | Director | Grant / award / vesting (derivative) | 25,319 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Allen Andrew R | Director | Grant / award / vesting (derivative) | 21,781 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Webster Stephen W | Director | Grant / award / vesting (derivative) | 25,319 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Meek David D. | Director | Grant / award / vesting (derivative) | 25,319 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Rosenberg Anthony | Director | Grant / award / vesting (derivative) | 25,319 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 4,000 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Open-market sale | 200 | $15.58 | $3.1K | Form 4 |
| 2026-05-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Open-market sale | 7,800 | $14.60 | $113.9K | Form 4 |
| 2026-05-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Option exercise / conversion | 4,000 | $4.30 | $17.2K | Form 4 |
| 2026-03-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 4,000 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Open-market sale | 8,000 | $15.68 | $125.4K | Form 4 |
| 2026-03-05 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Option exercise / conversion | 4,000 | $4.30 | $17.2K | Form 4 |
| 2026-02-25 | Michaelson Jennifer | Officer (Chief Scientific Officer) | Open-market sale | 1,780 | $14.14 | $25.2K | Form 4 |
Ask the chat about CGEM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CULLINAN THERAPEUTICS INC (CGEM).
Last updated 2026-07-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.